SCHEMBL5861387

SCHEMBL5861387

CS(=O)(=O)N(Cc1ccccc1)C1COc2c(C=O)cc(Br)cc2C1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DPP4 P27487 1/20 0.37
DPP9 Q86TI2 1/20 0.37
DPP7 Q9UHL4 1/20 0.37
MAPK1 P28482 1/20 0.36
FNTA P49354 1/20 0.35
FNTB P49356 1/20 0.35
SLC6A2 P23975 4/20 0.35
SLC6A4 P31645 3/20 0.35
KCNH2 Q12809 3/20 0.35
SLC6A3 Q01959 2/20 0.35
LMNA P02545 1/20 0.33
HTT P42858 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
MAPT P10636 1/20 0.32
ALDH1A1 P00352 1/20 0.31
CYP3A4 P08684 1/20 0.31
CYP2C9 P11712 1/20 0.31
TSHR P16473 1/20 0.31
CYP2C19 P33261 1/20 0.31
DRD2 P14416 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5861352 0.85 FNTA (0.46) DPP4DPP9DPP7MAPK1FNTA
SCHEMBL5860941 0.73 FNTA (0.47) DPP4DPP9DPP7MAPK1FNTA
SCHEMBL5862802 0.71 FNTA (0.44) DPP4DPP9DPP7MAPK1FNTA
SCHEMBL7238870 0.70 SLC6A2 (0.41) DPP4DPP9DPP7MAPK1FNTA
SCHEMBL5862052 0.69 DRD2 (0.30) DRD2
SCHEMBL5860957 0.67 FNTA (0.46) FNTAFNTBSLC6A2SLC6A4KCNH2
SCHEMBL5862857 0.66 FNTA (0.45) FNTAFNTBSLC6A2SLC6A4KCNH2
SCHEMBL7246925 0.60 FNTA (0.54) DPP4DPP9DPP7FNTAFNTB
SCHEMBL20722897 0.59 LTB4R (0.44) DRD2
SCHEMBL1512811 0.59 PARP1 (0.39) NPSR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7053223-B2 Inhibitors of farnesyl protein transferase BRISTOL-MYERS SQUIBB COMPANY (US) 2006-05-30 US disclosed
US-20040181068-A1 Inhibitors of farnesyl protein transferase BRISTOL-MYERS SQUIBB COMPANY 2004-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040181068-A1 Inhibitors of farnesyl protein transferase FNTA, FNTB, ACAT2 DPP4 1476/4885DPP9 725/4885DPP7 1267/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.